Sonnet BioTherapeutic News

Sonnet BioTherapeutics Files to Sell 5M Shares of Common Stock for Holders

Seeking AlphaMay 3 13:17 ET

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be partic

newsfileMay 3 09:00 ET

Express News | Sonnet Biotherapeutics Holdings: Post Purchase Agreement, Co Has Right From Time to Time at Option to Sell to Chardan up to Lesser of $25 Mln

ReutersMay 3 08:07 ET

Express News | Sonnet Biotherapeutics Holdings: On May 2, Entered Purchase Agreement, Registration Rights Agreement, Each With Chardan for “Chef,” Chardan’s Facility

ReutersMay 3 08:06 ET

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting Download as PDF March 19, 2024 7:30am EDT PRINCETON

Sonnet BioTherapeuticMar 19 07:30 ET

RNLX, ASLN and SONN Among Pre-market Losers

Seeking AlphaMar 12 08:28 ET

Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street

US equities were in red territory after Monday's opening bell as traders looked ahead to the consumer inflation report due for release later in the week for clues on the direction of the Federal Reser

MT NewswiresMar 11 09:49 ET

Top Premarket Gainers

Kidpik Corp. (PIK) shares soared more than three-fold Monday premarket following a 5.9% gain in the previous session. The L.S. Starrett Company (SCX) shares surged 56% after the company agreed to a ta

MT NewswiresMar 11 08:44 ET

Express News | Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB

Moomoo 24/7Mar 11 07:47 ET

Express News | Sonnet BioTherapeutics Says Early Safety Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy Met Study's Initial Pre-Specified Objective

Moomoo 24/7Mar 11 07:35 ET

Sonnet BioTherapeutics Announces Early Safety Data From the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‐080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability

AccesswireMar 11 07:30 ET

Express News | Sonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose Escalation

Moomoo 24/7Feb 29 16:46 ET

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today t

AccesswireFeb 29 16:05 ET

Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital

Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital

Dow JonesFeb 15 12:45 ET

Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating

Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating.

MT NewswiresFeb 15 09:08 ET

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersCogent Biosciences (NASDAQ:COGT) shares rose 45.6% to $7.95 during Wednesday's pre-market session. The company's market cap stands at $684.6 million. Lineage Cell Therapeutics (AMEX:LCTX) stock

BenzingaFeb 14 08:05 ET

Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate

Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.90) by 65.56 percent. This is a 98.24 percent increase over losses

BenzingaFeb 14 08:00 ET

Sonnet BioTherapeutics GAAP EPS of -$0.31

Seeking AlphaFeb 14 07:37 ET

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval and executed agreement

AccesswireFeb 14 07:30 ET

BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksJan 7 05:47 ET